US 10,245,251 B2 · Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck

Abstract

The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I); or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.

Claims5

Dependent claims

A method for the treatment of squamous cell carcinoma of head and neck in a subject comprising administering to said subject a therapeutically effective amount of:

a CDK inhibitor of formula I:
wherein Ar is 2-chloro-4-trifluoromethylphenyl;
or a pharmaceutically acceptable salt or solvate thereof;
and
a therapeutically effective amount of one or more antineoplastic agents selected from sorafenib, and lapatinib.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/206,185Filed 8 Jul 2016 · continuation

Priority

31 May 2011

Published

US 2017/0157090 A18 Jun 2017

Granted

2 Apr 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 31/4025
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: not condensed and…
A61K 31/282
Compounds containing heavy metals: platinum compounds
A61K 31/337
Having oxygen as the only ring hetero atom, e.g. fungichromin: having four-membered rings, e.g. taxol
A61K 31/44
Having six-membered rings with one nitrogen as the only ring hetero atom: non condensed pyridines; Hydrogenated derivatives thereof

Family

Application61/491,569Us provisional application · filed 31 May 2011

PCT/IB2012/052698Parent of this continuation · filed 30 May 2012

US 2017/0157090 A1Pre-grant publication · published 8 Jun 2017

Application14/122,922Parent of this continuation

US 2014/0112918 A1Published application

US 10,245,251 B2This patent

From the US filing history. Foreign family members aren’t listed.

Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck

Life of this patent

Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck

Life of this patent

Abstract

Claims5